{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:11:36Z","timestamp":1790223096520,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jconrel.2022.11.028","type":"journal-article","created":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T06:16:54Z","timestamp":1669961814000},"page":"289-302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Comprehensive evaluation of biopolymer immune implants for peritoneal metastasis carcinoma therapy"],"prefix":"10.1016","volume":"353","author":[{"given":"Xinghui","family":"Si","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guofeng","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wantong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuesi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jconrel.2022.11.028_bb0005","first-page":"209","article-title":"Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"24","key":"10.1016\/j.jconrel.2022.11.028_bb0010","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe3839","article-title":"High-throughput functional screening for next-generation cancer immunotherapy using droplet-based microfluidics","volume":"7","author":"Wang","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2022.11.028_bb0015","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jconrel.2020.01.021","article-title":"Hypoxia-sensitive supramolecular nanogels for the cytosolic delivery of ribonuclease A as a breast cancer therapeutic","volume":"320","author":"Si","year":"2020","journal-title":"J. Control. Release"},{"issue":"18","key":"10.1016\/j.jconrel.2022.11.028_bb0020","doi-asserted-by":"crossref","first-page":"7219","DOI":"10.1002\/anie.202000947","article-title":"Tumor microenvironment-activated NIR-II nanotheranostic system for precise diagnosis and treatment of peritoneal metastasis","volume":"59","author":"Ling","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"issue":"11","key":"10.1016\/j.jconrel.2022.11.028_bb0025","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.02745","article-title":"Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1\/2 mutation (SOLO3): a randomized phase III trial","volume":"38","author":"Penson","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"32","key":"10.1016\/j.jconrel.2022.11.028_bb0030","doi-asserted-by":"crossref","first-page":"11385","DOI":"10.1039\/D0DT01476A","article-title":"Investigation into antiproliferative activity and apoptosis mechanism of new arene Ru(II) carbazole-based hydrazone complexes","volume":"49","author":"Kamatchi","year":"2020","journal-title":"Dalton Trans."},{"issue":"10","key":"10.1016\/j.jconrel.2022.11.028_bb0035","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa010187","article-title":"Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction","volume":"345","author":"Macdonald","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2022.11.028_bb0040","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jconrel.2022.11.028_bb0045","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.jconrel.2022.11.028_bb0050","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","article-title":"Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"30","author":"Chua","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2022.11.028_bb0055","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.canlet.2018.01.050","article-title":"Immunogenic chemotherapy: dose and schedule dependence and combination with immunotherapy","volume":"419","author":"Wu","year":"2018","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.jconrel.2022.11.028_bb0060","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic Leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.jconrel.2022.11.028_bb0065","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin. Proc."},{"issue":"3","key":"10.1016\/j.jconrel.2022.11.028_bb0070","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/annonc\/mdy518","article-title":"Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann. Oncol."},{"issue":"14","key":"10.1016\/j.jconrel.2022.11.028_bb0075","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2022.11.028_bb0080","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur. Urol."},{"issue":"6477","key":"10.1016\/j.jconrel.2022.11.028_bb0085","doi-asserted-by":"crossref","DOI":"10.1126\/science.aax0182","article-title":"Neoadjuvant checkpoint blockade for cancer immunotherapy","volume":"367","author":"Topalian","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jconrel.2022.11.028_bb0090","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.jconrel.2022.11.028_bb0095","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.jconrel.2022.11.028_bb0100","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.1016\/j.jaci.2005.09.034","article-title":"Overview of the human immune response","volume":"117","author":"Chaplin","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2 Suppl","key":"10.1016\/j.jconrel.2022.11.028_bb0105","doi-asserted-by":"crossref","first-page":"S442","DOI":"10.1067\/mai.2003.125","article-title":"1. Overview of the immune response","volume":"111","author":"Chaplin","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2022.11.028_bb0110","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13024-021-00453-4","article-title":"Modulating innate immune activation states impacts the efficacy of specific a beta immunotherapy","volume":"16","author":"Levites","year":"2021","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.jconrel.2022.11.028_bb0115","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jconrel.2017.08.006","article-title":"Injectable hydrogels for sustained release of therapeutic agents","volume":"267","author":"Thambi","year":"2017","journal-title":"J. Control. Release"},{"issue":"7","key":"10.1016\/j.jconrel.2022.11.028_bb0120","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1039\/C4NR05897F","article-title":"Nanostructure controlled sustained delivery of human growth hormone using injectable, biodegradable, pH\/temperature responsive nanobiohybrid hydrogel","volume":"7","author":"Singh","year":"2015","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2022.11.028_bb0125","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.biomaterials.2015.05.025","article-title":"Enhancing neurogenesis and angiogenesis with target delivery of stromal cell derived factor-1alpha using a dual ionic pH-sensitive copolymer","volume":"61","author":"Kim","year":"2015","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.jconrel.2022.11.028_bb0130","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ijrobp.2020.07.2326","article-title":"Potentiating antitumor efficacy through radiation and sustained intratumoral delivery of anti-CD40 and anti-PDL1","volume":"110","author":"Liu","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.jconrel.2022.11.028_bb0135","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.actbio.2021.10.039","article-title":"In situ gel implant for postsurgical wound management and extended chemoimmunotherapy against breast cancer recurrence","volume":"138","author":"Wang","year":"2022","journal-title":"Acta Biomater."},{"issue":"42","key":"10.1016\/j.jconrel.2022.11.028_bb0140","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201903242","article-title":"A designer scaffold with immune nanoconverters for reverting immunosuppression and enhancing immune checkpoint blockade therapy","volume":"31","author":"Phuengkham","year":"2019","journal-title":"Adv. Mater."},{"issue":"1","key":"10.1016\/j.jconrel.2022.11.028_bb0145","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/s41467-022-29121-x","article-title":"Thermosensitive hydrogel releasing nitric oxide donor and anti-CTLA-4 micelles for anti-tumor immunotherapy","volume":"13","author":"Kim","year":"2022","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.jconrel.2022.11.028_bb0150","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202004559","article-title":"Biopolymer immune implants\u2019 sequential activation of innate and adaptive immunity for colorectal cancer postoperative immunotherapy","volume":"33","author":"Ji","year":"2021","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2022.11.028_bb0155","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1021\/acs.nanolett.9b05265","article-title":"A rationally designed polymer conjugate for tumor-specific amplification of oxidative stress and boosting anti-tumor immunity","author":"Ma","year":"2020","journal-title":"Nano Lett."},{"issue":"9","key":"10.1016\/j.jconrel.2022.11.028_bb0160","doi-asserted-by":"crossref","first-page":"5281","DOI":"10.1021\/acsbiomaterials.0c00840","article-title":"Biodegradable implants combined with immunogenic chemotherapy and immune checkpoint therapy for peritoneal metastatic carcinoma postoperative treatment","volume":"6","author":"Si","year":"2020","journal-title":"ACS Biomater. Sci. Eng."},{"issue":"3","key":"10.1016\/j.jconrel.2022.11.028_bb0165","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.carbpol.2007.04.002","article-title":"Mechanical properties and degradation behaviors of hyaluronic acid hydrogels cross-linked at various cross-linking densities","volume":"70","author":"Jeon","year":"2007","journal-title":"Carbohydr. Polym."},{"issue":"2","key":"10.1016\/j.jconrel.2022.11.028_bb0170","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.polymer.2010.11.058","article-title":"Insight on the periodate oxidation of dextran and its structural vicissitudes","volume":"52","author":"Maia","year":"2011","journal-title":"Polymer"},{"key":"10.1016\/j.jconrel.2022.11.028_bb0175","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.mrfmmm.2016.02.005","article-title":"Aldehydes with high and low toxicities inactivate cells by damaging distinct cellular targets","volume":"786","author":"Xie","year":"2016","journal-title":"Mutat. Res."},{"key":"10.1016\/j.jconrel.2022.11.028_bb0180","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1038\/s41467-018-04605-x","article-title":"Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap","volume":"9","author":"Song","year":"2018","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.jconrel.2022.11.028_bb0185","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/sj.leu.2404763","article-title":"Proinflammatory response of human leukemic cells to dsRNA transfection linked to activation of dendritic cells","volume":"21","author":"Smits","year":"2007","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.jconrel.2022.11.028_bb0190","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41551-018-0236-8","article-title":"TLR7\/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy","volume":"2","author":"Rodell","year":"2018","journal-title":"Nat. Biomed. Eng."},{"issue":"1","key":"10.1016\/j.jconrel.2022.11.028_bb0195","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1038\/s41467-019-12657-w","article-title":"The TLR7\/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer","volume":"10","author":"Michaelis","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2022.11.028_bb0200","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/s41467-021-22311-z","article-title":"Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors","volume":"12","author":"Bahmani","year":"2021","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.jconrel.2022.11.028_bb0205","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s11427-010-0045-0","article-title":"Plasmacytoid dendritic cells in antiviral immunity and autoimmunity","volume":"53","author":"Tang","year":"2010","journal-title":"Sci. China Life Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2022.11.028_bb0210","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1128\/JVI.79.1.17-27.2005","article-title":"Plasmacytoid dendritic cells: linking innate and adaptive immunity","volume":"79","author":"McKenna","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2022.11.028_bb0215","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41551-018-0236-8","article-title":"TLR7\/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy","volume":"2","author":"Rodell","year":"2018","journal-title":"Nat. Biomed. Eng."},{"issue":"39","key":"10.1016\/j.jconrel.2022.11.028_bb0220","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb4639","article-title":"An implantable blood clot-based immune niche for enhanced cancer vaccination","volume":"6","author":"Fan","year":"2020","journal-title":"Sci. Adv."},{"issue":"2","key":"10.1016\/j.jconrel.2022.11.028_bb0225","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3390\/cancers13020167","article-title":"IL-12 family cytokines in cancer and immunotherapy","volume":"13","author":"Mirlekar","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.jconrel.2022.11.028_bb0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054126","article-title":"Poly(I:C)\/alum mixed adjuvant priming enhances HBV subunit vaccine-induced immunity in mice when combined with recombinant adenoviral-based HBV vaccine boosting","volume":"8","author":"Chuai","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2022.11.028_bb0235","doi-asserted-by":"crossref","first-page":"13193","DOI":"10.1038\/ncomms13193","article-title":"Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy","volume":"7","author":"Chen","year":"2016","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2022.11.028_bb0240","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1080\/10717544.2021.1938756","article-title":"PLGA-based biodegradable microspheres in drug delivery: recent advances in research and application","volume":"28","author":"Su","year":"2021","journal-title":"Drug Deliv."},{"issue":"10","key":"10.1016\/j.jconrel.2022.11.028_bb0245","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz4204","article-title":"Localized cocktail chemoimmunotherapy after in situ gelation to trigger robust systemic antitumor immune responses","volume":"6","author":"Chao","year":"2020","journal-title":"Sci. Adv."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922007738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922007738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:35:15Z","timestamp":1759163715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365922007738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":49,"alternative-id":["S0168365922007738"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.11.028","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive evaluation of biopolymer immune implants for peritoneal metastasis carcinoma therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.11.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}